MedTrace Logo

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

NCT05625633 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-04-05

No results posted yet for this study

Summary

This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.

Conditions

  • Warts

Interventions

BIOLOGICAL

Human Papillomavirus 9-valent Vaccine, Recombinant

0.5-mL suspension of 9-valent Gardasil administered as intramuscular injection at weeks 0, 4, and 20

OTHER

Normal Saline

0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20

Sponsors & Collaborators

Principal Investigators

  • Lowell Nicholson, MD · University of Utah Health Care System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-25
Primary Completion
2025-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05625633 on ClinicalTrials.gov